Servier and IDEAYA Join Forces to Develop Darovasertib for Uveal Melanoma Patients Globally Servier and IDEAYA Biosciences have partnered to expedite the global development of darovasertib, a promising treatment for uveal melanoma, enhancing patient access to essential care.

Servier and IDEAYA Join Forces to Develop Darovasertib for Uveal Melanoma Patients Globally #France #IDEAYA #darovasertib #Servier #Suresnes

IDEAYA Biosciences to Showcase Groundbreaking Survival Data on Darovasertib and Crizotinib in Uveal Melanoma IDEAYA Biosciences is set to present significant survival data from their Phase 2 trial of darovasertib and crizotinib for metastatic uveal melanoma at the 2025 SMR Congress in Amsterdam.

IDEAYA Biosciences to Showcase Groundbreaking Survival Data on Darovasertib and Crizotinib in Uveal Melanoma #United_States #South_San_Francisco #IDEAYA #darovasertib #crizotinib

IDEAYA Prepares for AACR 2025 Presentation Focused on Innovative Cancer Treatments with IDE275 (GSK959) IDEAYA Biosciences gears up for AACR 2025, showcasing IDE275 (GSK959) for MSI-H cancers, revealing promising results and collaboration details.

IDEAYA Prepares for AACR 2025 Presentation Focused on Innovative Cancer Treatments with IDE275 (GSK959) #United_States #Chicago #Cancer_Research #IDEAYA #GSK959

IDEAYA Biosciences Collaborates with ATTMOS for Breakthrough in Oncology Drug Discovery IDEAYA Biosciences partners with ATTMOS to revolutionize drug discovery using AI and machine learning, targeting previously undruggable cancers.

IDEAYA Biosciences Collaborates with ATTMOS for Breakthrough in Oncology Drug Discovery #United_States #oncology #South_San_Francisco #IDEAYA #ATTMOS

IDEAYA Biosciences and Gilead Join Forces for Promising Clinical Study on NSCLC Treatment IDEAYA Biosciences has partnered with Gilead Sciences to evaluate the promising combination therapy involving IDE397 and Trodelvy for NSCLC patients. This collaboration aims to address MTAP deletions.

IDEAYA Biosciences and Gilead Join Forces for Promising Clinical Study on NSCLC Treatment #United_States #South_San_Francisco #IDEAYA #Gilead #Trodelvy

IDEAYA Biosciences Partners with Hengrui Pharma to Develop Novel SHR-4849 for Cancer Treatment IDEAYA Biosciences has secured an exclusive license with Hengrui Pharma for the promising SHR-4849, targeting DLL3 in SCLC and NET tumors. This collaboration aims to address significant unmet medical needs in oncology.

IDEAYA Biosciences Partners with Hengrui Pharma to Develop Novel SHR-4849 for Cancer Treatment #United_States #South_San_Francisco #IDEAYA #Hengrui_Pharma #SHR-4849

IDEAYA Biosciences Nominates IDE251 for Targeting Amplified Tumors in Breast and Lung Cancer IDEAYA Biosciences has nominated IDE251, a potential KAT6/7 dual inhibitor aimed at treating breast and lung cancers associated with 8p11 amplification.

IDEAYA Biosciences Nominates IDE251 for Targeting Amplified Tumors in Breast and Lung Cancer #USA #South_San_Francisco #IDEAYA #IDE251 #KAT6/7

IDEAYA Biosciences Sets Agenda for Upcoming Investor R&D Day on December 16, 2024 IDEAYA Biosciences will host a virtual R&D Day on December 16, 2024, focusing on precision medicine and oncology advancements. Don't miss it!

IDEAYA Biosciences Sets Agenda for Upcoming Investor R&D Day on December 16, 2024 #USA #oncology #South_San_Francisco #Precision_Medicine #IDEAYA